PLEASANTON, Calif.,
Jan. 30, 2015 /PRNewswire/
-- Thoratec Corporation (NASDAQ: THOR), a world leader in
device-based mechanical circulatory support therapies to save,
support and restore failing hearts, said today it will be
participating in the Leerink Global Healthcare Conference on
Thursday, February 12.
Taylor C. Harris, Vice President
and Chief Financial Officer, will provide an update on the company
beginning at 10:45 a.m., Eastern Standard
Time (7:45 a.m., Pacific Standard
Time).
The presentation will be available through the conference
website at
http://leerink.metameetings.com/confbook/healthcare15/directlink?ticker=THOR,
or on the company's website at http://www.thoratec.com.
Thoratec is a world leader in therapies to address
advanced-stage heart failure. The company's products include
the HeartMate II® and HeartMate III™ LVAS (Left Ventricular Assist
Systems) and Thoratec® VAD (Ventricular Assist Device) with more
than 20,000 devices implanted in patients suffering from heart
failure. Thoratec also manufactures and distributes the CentriMag®,
PediMag®/PediVAS®, and HeartMate PHP™ product lines. HeartMate
III is an investigational device and is limited by US law to
investigational use. HeartMate PHP is currently in development and
not approved for sale. Thoratec is headquartered in Pleasanton, California. For more information,
visit the company's website at http://www.thoratec.com.
Thoratec, the Thoratec logo, HeartMate, and HeartMate II are
registered trademarks of Thoratec Corporation and HeartMate III,
HeartMate PHP, and IVAD are trademarks of Thoratec Corporation.
CentriMag and PediMag are registered trademarks of Thoratec LLC,
and PediVAS is a registered trademark of Thoratec Switzerland
GmbH.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/thoratec-presentation-at-leerink-global-healthcare-conference-to-be-webcast-300027488.html
SOURCE Thoratec Corporation